Life SciencesPharmaceuticalsDrug Discovery

Transplant Complications Drug Development Pipeline Review, 2018

Lowest Prices Guaranteed Length Publisher Published Date SKU
from $3,995 173 Pages GBI Research November, 2018 XGBR15846974
Lowest Prices Guaranteed
Price from $3,995
Length 173 Pages
Publisher GBI Research
Published Date November, 2018
SKU XGBR15846974

Transplant Complications Drug Development Pipeline Review, 2018

Summary

GVHD is a complication that can occur after a stem cell or bone marrow transplant and involves the newly transplanted donor cells attacking the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment consists of immunosuppressants. There are 125 products in development for GVHD.

Organ transplantation replaces an injured or diseased organ with a healthy one. Following a transplant, the immune system may consider the transplanted tissue as foreign and work against it. Patients can develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously.

These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses, blocking organ rejection and facilitating a successful transplant. There are 18 products in development for liver transplant rejection, 49 products in development for kidney transplant rejection and 12 products in development for lung transplant rejection.

Molecular targets acted on by products in development for transplantation complications include tyrosine kinases, caspases and chemokine receptors. Companies operating in this pipeline space include Medeor Therapeutics, Amgen and Novartis.

This report “Transplant Complications Drug Development Pipeline Review, 2018”, provides an overview of the pipeline landscape for transplant complications. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), liver transplant rejection, kidney transplant rejection and lung transplant rejection and features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Transplant Complications Report Coverage
2.2 Graft Versus Host Disease (GVHD) - Overview
2.3 Liver Transplant Rejection - Overview
2.4 Kidney Transplant Rejection - Overview
2.5 Lung Transplant Rejection - Overview
3 Therapeutics Development
3.1 Graft Versus Host Disease (GVHD)
3.2 Liver Transplant Rejection
3.3 Kidney Transplant Rejection
3.4 Lung Transplant Rejection
4 Therapeutics Assessment
4.1 Graft Versus Host Disease (GVHD)
4.2 Liver Transplant Rejection
4.3 Kidney Transplant Rejection
4.4 Lung Transplant Rejection
5 Companies Involved in Therapeutics Development
5.1 Graft Versus Host Disease (GVHD)
5.2 Liver Transplant Rejection
5.3 Kidney Transplant Rejection
5.4 Lung Transplant Rejection
6 Dormant Projects
6.1 Graft Versus Host Disease (GVHD)
6.2 Liver Transplant Rejection
6.3 Kidney Transplant Rejection
6.4 Lung Transplant Rejection
7 Discontinued Products
7.1 Graft Versus Host Disease (GVHD)
7.2 Liver Transplant Rejection
7.3 Kidney Transplant Rejection
8 Product Development Milestones
8.1 Graft Versus Host Disease (GVHD)
8.2 Liver Transplant Rejection
8.3 Kidney Transplant Rejection
8.4 Lung Transplant Rejection
9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer
1.1 List of Tables
Table 1: Number of Products under Development for Graft Versus Host Disease (GVHD)
Table 2: Number of Products under Development by Companies, Graft Versus Host Disease (GVHD)
Table 3: Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)
Table 4: Products under Development by Companies, Graft Versus Host Disease (GVHD)
Table 5: Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)
Table 6: Number of Products under Development for Liver Transplant Rejection
Table 7: Number of Products under Development by Companies, Liver Transplant Rejection
Table 8: Number of Products under Development by Universities/Institutes, Liver Transplant Rejection
Table 9: Products under Development by Companies, Liver Transplant Rejection
Table 10: Products under Development by Universities/Institutes, Liver Transplant Rejection
Table 11: Number of Products under Development for Kidney Transplant Rejection
Table 12: Number of Products under Development by Companies, Kidney Transplant Rejection
Table 13: Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection
Table 14: Products under Development by Companies, Kidney Transplant Rejection
Table 15: Products under Development by Universities/Institutes, Kidney Transplant Rejection
Table 16: Number of Products under Development for Lung Transplant Rejection
Table 17: Number of Products under Development by Companies, Lung Transplant Rejection
Table 18: Products under Development by Companies, Lung Transplant Rejection
Table 19: Number of Products by Stage and Target, Graft Versus Host Disease (GVHD)
Table 20: Number of Products by Stage and Mechanism of Action, Graft Versus Host Disease (GVHD)
Table 21: Number of Products by Stage and Route of Administration, Graft Versus Host Disease (GVHD)
Table 22: Number of Products by Stage and Molecule Type, Graft Versus Host Disease (GVHD)
Table 23: Number of Products by Stage and Target, Liver Transplant Rejection
Table 24: Number of Products by Stage and Mechanism of Action, Liver Transplant Rejection
Table 25: Number of Products by Stage and Route of Administration, Liver Transplant Rejection
Table 26: Number of Products by Stage and Molecule Type, Liver Transplant Rejection
Table 27: Number of Products by Stage and Target, Kidney Transplant Rejection
Table 28: Number of Products by Stage and Mechanism of Action, Kidney Transplant Rejection
Table 29: Number of Products by Stage and Route of Administration, Kidney Transplant Rejection
Table 30: Number of Products by Stage and Molecule Type, Kidney Transplant Rejection
Table 31: Number of Products by Stage and Target, Lung Transplant Rejection
Table 32: Number of Products by Stage and Mechanism of Action, Lung Transplant Rejection
Table 33: Number of Products by Stage and Route of Administration, Lung Transplant Rejection
Table 34: Number of Products by Stage and Molecule Type, Lung Transplant Rejection
Table 35: Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc
Table 36: Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc
Table 37: Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc
Table 38: Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc
Table 39: Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH
Table 40: Graft Versus Host Disease (GVHD) - Pipeline by Aptevo Therapeutics Inc
Table 41: Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc
Table 42: Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc
Table 43: Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc
Table 44: Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Co
Table 45: Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc
Table 46: Graft Versus Host Disease (GVHD) - Pipeline by Cell2B Advanced Therapeutics SA
Table 47: Graft Versus Host Disease (GVHD) - Pipeline by Cellect Biotechnology Ltd
Table 48: Graft Versus Host Disease (GVHD) - Pipeline by Cellective BioTherapy Inc
Table 49: Graft Versus Host Disease (GVHD) - Pipeline by CSL Ltd
Table 50: Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Ltd
Table 51: Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc
Table 52: Graft Versus Host Disease (GVHD) - Pipeline by Elsalys Biotech SA
Table 53: Graft Versus Host Disease (GVHD) - Pipeline by enGene Inc
Table 54: Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd
Table 55: Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd
Table 56: Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics Inc
Table 57: Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corp Ltd
Table 58: Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc
Table 59: Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corp
Table 60: Graft Versus Host Disease (GVHD) - Pipeline by Inspyr Therapeutics Inc
1.2 List of Figures
Figure 1: Number of Products under Development for Graft Versus Host Disease (GVHD)
Figure 2: Number of Products under Development by Companies, Graft Versus Host Disease (GVHD)
Figure 3: Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)
Figure 4: Number of Products under Development for Liver Transplant Rejection
Figure 5: Number of Products under Development by Companies, Liver Transplant Rejection
Figure 6: Number of Products under Development by Universities/Institutes, Liver Transplant Rejection
Figure 7: Number of Products under Development for Kidney Transplant Rejection
Figure 8: Number of Products under Development by Companies, Kidney Transplant Rejection
Figure 9: Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection
Figure 10: Number of Products under Development for Lung Transplant Rejection
Figure 11: Number of Products under Development by Companies, Lung Transplant Rejection
Figure 12: Number of Products by Top 10 Targets, Graft Versus Host Disease (GVHD)
Figure 13: Number of Products by Stage and Top 10 Targets, Graft Versus Host Disease (GVHD)
Figure 14: Number of Products by Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD)
Figure 15: Number of Products by Stage and Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD)
Figure 16: Number of Products by Routes of Administration, Graft Versus Host Disease (GVHD)
Figure 17: Number of Products by Stage and Routes of Administration, Graft Versus Host Disease (GVHD)
Figure 18: Number of Products by Top 10 Molecule Types, Graft Versus Host Disease (GVHD)
Figure 19: Number of Products by Stage and Top 10 Molecule Types, Graft Versus Host Disease (GVHD)
Figure 20: Number of Products by Top 10 Targets, Liver Transplant Rejection
Figure 21: Number of Products by Stage and Top 10 Targets, Liver Transplant Rejection
Figure 22: Number of Products by Top 10 Mechanism of Actions, Liver Transplant Rejection
Figure 23: Number of Products by Stage and Top 10 Mechanism of Actions, Liver Transplant Rejection
Figure 24: Number of Products by Routes of Administration, Liver Transplant Rejection
Figure 25: Number of Products by Stage and Routes of Administration, Liver Transplant Rejection
Figure 26: Number of Products by Molecule Types, Liver Transplant Rejection
Figure 27: Number of Products by Stage and Molecule Types, Liver Transplant Rejection
Figure 28: Number of Products by Top 10 Targets, Kidney Transplant Rejection
Figure 29: Number of Products by Stage and Top 10 Targets, Kidney Transplant Rejection
Figure 30: Number of Products by Top 10 Mechanism of Actions, Kidney Transplant Rejection
Figure 31: Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Transplant Rejection
Figure 32: Number of Products by Routes of Administration, Kidney Transplant Rejection
Figure 33: Number of Products by Stage and Routes of Administration, Kidney Transplant Rejection
Figure 34: Number of Products by Top 10 Molecule Types, Kidney Transplant Rejection
Figure 35: Number of Products by Stage and Top 10 Molecule Types, Kidney Transplant Rejection
Figure 36: Number of Products by Targets, Lung Transplant Rejection
Figure 37: Number of Products by Stage and Targets, Lung Transplant Rejection
Figure 38: Number of Products by Mechanism of Actions, Lung Transplant Rejection
Figure 39: Number of Products by Stage and Mechanism of Actions, Lung Transplant Rejection
Figure 40: Number of Products by Routes of Administration, Lung Transplant Rejection
Figure 41: Number of Products by Stage and Routes of Administration, Lung Transplant Rejection
Figure 42: Number of Products by Molecule Types, Lung Transplant Rejection
Figure 43: Number of Products by Stage and Molecule Types, Lung Transplant Rejection

$3,995
$7,990
$11,985

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks